Repligen Co. (NASDAQ:RGEN – Get Rating) CFO Jon Snodgres sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $220.00, for a total transaction of $440,000.00. Following the completion of the transaction, the chief financial officer now owns 37,187 shares of the company’s stock, valued at approximately $8,181,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Repligen Price Performance
Shares of RGEN opened at $240.40 on Thursday. The firm has a market capitalization of $13.08 billion, a PE ratio of 95.02 and a beta of 1.07. The company’s 50-day moving average is $171.99 and its 200-day moving average is $173.32. Repligen Co. has a fifty-two week low of $137.21 and a fifty-two week high of $327.32.
Repligen (NASDAQ:RGEN – Get Rating) last issued its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.19. Repligen had a net margin of 19.86% and a return on equity of 11.13%. The company had revenue of $207.63 million for the quarter, compared to analyst estimates of $189.06 million. During the same period in the prior year, the firm earned $0.79 earnings per share. The company’s revenue was up 27.4% on a year-over-year basis. Analysts predict that Repligen Co. will post 3.1 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Repligen
Analysts Set New Price Targets
RGEN has been the subject of several research analyst reports. SVB Leerink reiterated a “maintains” rating on shares of Repligen in a report on Wednesday. Craig Hallum reduced their target price on shares of Repligen from $286.00 to $274.00 in a report on Thursday, April 28th. Stephens upped their price target on shares of Repligen from $220.00 to $275.00 and gave the stock an “overweight” rating in a research report on Wednesday. UBS Group began coverage on shares of Repligen in a research report on Wednesday, July 20th. They set a “buy” rating and a $213.00 price target on the stock. Finally, KeyCorp upped their price target on shares of Repligen from $245.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $276.00.
Repligen Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Get a free copy of the StockNews.com research report on Repligen (RGEN)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.